# Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )

> **NCT04750707** · PHASE3 · COMPLETED · sponsor: **Global Health Uganda LTD** · enrollment: 270 (actual)

## Conditions studied

- Sickle Cell Anemia in Children

## Interventions

- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT04750707
- **Lead sponsor:** Global Health Uganda LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-09
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2025-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04750707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04750707, "Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04750707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*